Biocoll Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Biocoll Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $202.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biocoll Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $202.3K Trade | TransData Nexus

Biocoll Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $202.3K Total Trade · DGFT Verified

Biocoll Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $202.3K across 2 products in 1 therapeutic categories. Based on 8 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftazidime ($200.0K), Gatifloxacin ($2.3K), .

Biocoll Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Biocoll Pharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Biocoll Pharmaceuticals Private Limited? — Company Overview & Market Position

Biocoll Pharmaceuticals Private Limited, established in 2004 by Mr. Jitender Saini, is a Delhi-based pharmaceutical company specializing in the manufacturing and export of finished pharmaceutical formulations. The company is registered under the Corporate Identification Number (CIN) U74999DL2015PTC279199, with its registered office located at House No. 821, Gali No. 50, Lekhu Nagar, Tri Nagar, Delhi, India. As of March 2023, Biocoll Pharmaceuticals reported a paid-up capital of ₹100,000, indicating a modest financial scale. The company employs approximately 20 professionals dedicated to delivering high-quality pharmaceutical products.

What Does Biocoll Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftazidime$200.0K 2Gatifloxacin$2.3K

Biocoll Pharmaceuticals Private Limited Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Biocoll Pharmaceuticals Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftazidime	Advanced Antibiotics	$200.0K	4	1.9%	6
2	Gatifloxacin	Advanced Antibiotics	$2.3K	4	0.3%	8

Biocoll Pharmaceuticals Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $202.3K. The top category is Advanced Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Biocoll Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Biocoll Pharmaceuticals operates a manufacturing unit in Delhi, India, where it produces a range of pharmaceutical products, including antibiotics and pet medications. The facility is equipped with advanced machinery to ensure the production of high-quality formulations. While specific production capacities are not publicly disclosed, the company's focus on quality assurance and adherence to regulatory standards suggest a commitment to maintaining stringent manufacturing processes.

3Key Leadership

The leadership team at Biocoll Pharmaceuticals is headed by Mr. Jitender Saini, who serves as the Managing Director. His extensive experience in the pharmaceutical industry has been instrumental in the company's growth and strategic direction. Other key executives include Poonam, who holds the position of Director, contributing to the company's operational and strategic initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Biocoll Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Biocoll Pharmaceuticals has made efforts to expand its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has engaged in the research, development, manufacturing, sourcing, marketing, and distribution of pharmaceutical products, indicating a proactive approach to meeting international standards. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly available. This lack of transparency may pose challenges for potential partners and customers seeking to assess the company's compliance with international regulatory requirements.

2Emerging Markets

Biocoll Pharmaceuticals has also targeted emerging markets in Africa, Latin America, and Southeast Asia. The company's focus on providing high-quality pharmaceutical products at competitive prices aligns with the needs of these regions. While the company has engaged in the research, development, manufacturing, sourcing, marketing, and distribution of pharmaceutical products, specific information regarding WHO prequalification or other certifications enabling access to these markets is not publicly disclosed. This lack of information may limit the company's ability to fully capitalize on opportunities in these regions.

Geographic Strategy

Biocoll Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Biocoll Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. This lack of transparency may pose challenges for potential partners and customers seeking to assess the company's compliance with FDA regulations and standards.

2WHO & EU GMP

Information regarding Biocoll Pharmaceuticals' compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. This absence of information may limit the company's ability to demonstrate adherence to international quality standards, potentially affecting its competitiveness in global markets.

3CDSCO & Indian Regulatory

Biocoll Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Biocoll Pharmaceuticals operates in a competitive landscape with numerous pharmaceutical companies offering similar products. While the company has a modest export value of $202,000 USD across eight shipments, with Ceftazidime accounting for $200,000 USD and Gatifloxacin $2,000 USD, it holds a 1.9% and 0.3% market share in these products, respectively. This indicates that Biocoll Pharmaceuticals faces significant competition in its product categories. The company's portfolio concentration, with its top five products accounting for 100% of exports, suggests a lack of diversification, which could be a strategic risk.

2Key Differentiators

Biocoll Pharmaceuticals' key differentiators include its commitment to quality assurance and customer-centric approach. The company emphasizes understanding customer needs and delivering high-quality products, as evidenced by its mission to supply dependable and first-class products and services in a cost-effective manner. Additionally, the company's focus on continuous improvement and innovation positions it to adapt to changing market demands.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Biocoll Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Biocoll Pharmaceuticals has a track record of supplying pharmaceutical products to a range of clients, from small startups to large pharmaceutical companies. The company's annual turnover is reported to be between ₹2.5 to 5 crore, indicating a moderate scale of operations. While the company has engaged in the research, development, manufacturing, sourcing, marketing, and distribution of pharmaceutical products, specific details regarding export volume consistency and reliability indicators are not publicly available. This lack of transparency may pose challenges for potential partners and customers seeking to assess the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Biocoll Pharmaceuticals as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards to ensure product quality.

Frequently Asked Questions — Biocoll Pharmaceuticals Private Limited

How many pharmaceutical products does Biocoll Pharmaceuticals Private Limited export from India?

Biocoll Pharmaceuticals Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Ceftazidime ($200.0K), Gatifloxacin ($2.3K). Total export value is $202.3K.

What is Biocoll Pharmaceuticals Private Limited's total pharmaceutical export value?

Biocoll Pharmaceuticals Private Limited's total pharmaceutical export value is $202.3K, based on 8 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Biocoll Pharmaceuticals Private Limited cover?

Biocoll Pharmaceuticals Private Limited exports across 1 therapeutic categories. The largest are Advanced Antibiotics (100.0%, 2 products).

Get Full Biocoll Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.